With the accumulating insights, it becomes apparent that Gal-1, especially when expressed by activated PSCs, could serve as a potent target for immunotherapeutic strategies in treating pancreatic cancer. This evidence concerns the gene LGALS1 and familial pancreatic carcinoma.